N
SGMO

Nuveen’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Nuveen’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-737,464
Closed -$494K – 3405
2024
Q1 		$494K Hold
737,464
– – ﹤0.01% 2978
2023
Q4 		$401K Buy
737,464
+20,936
+3% +$9.65K ﹤0.01% 3075
2023
Q3 		$430K Sell
716,528
-2,775
-0.4% -$2.97K ﹤0.01% 2891
2023
Q2 		$935K Sell
719,303
-664,326
-48% -$908K ﹤0.01% 2691
2023
Q1 		$2.44M Sell
1,383,629
-1,948,972
-58% -$5.56M ﹤0.01% 2260
2022
Q4 		$10.5M Sell
3,332,601
-23,228
-0.7% -$90.1K ﹤0.01% 1459
2022
Q3 		$16.4M Buy
3,355,829
+2,267,632
+208% +$11.6M 0.01% 1148
2022
Q2 		$4.5M Sell
1,088,197
-144,010
-12% -$623K ﹤0.01% 2012
2022
Q1 		$7.12M Sell
1,232,207
-64,659
-5% -$384K ﹤0.01% 1855
2021
Q4 		$9.26M Sell
1,296,866
-137,659
-10% -$1.2M ﹤0.01% 1745
2021
Q3 		$13.7M Buy
1,434,525
+36,079
+3% +$357K ﹤0.01% 1553
2021
Q2 		$16.7M Sell
1,398,446
-59,903
-4% -$678K 0.01% 1509
2021
Q1 		$18.3M Buy
1,458,349
+18,089
+1% +$244K 0.01% 1392
2020
Q4 		$22.5M Buy
1,440,260
+73,749
+5% +$864K 0.01% 1190
2020
Q3 		$12.9M Buy
1,366,511
+662,875
+94% +$7.17M 0.01% 1346
2020
Q2 		$6.3M Buy
703,636
+26,370
+4% +$245K ﹤0.01% 1767
2020
Q1 		$4.31M Sell
677,266
-95,582
-12% -$709K ﹤0.01% 1797
2019
Q4 		$6.47M Buy
772,848
+32,337
+4% +$297K ﹤0.01% 1847
2019
Q3 		$6.7M Sell
740,511
-50,171
-6% -$563K ﹤0.01% 1798
2019
Q2 		$8.52M Buy
+790,682
New +$8.41M ﹤0.01% 1699

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen's SGMO Position: Q2 2024 in Review

Nuveen sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2024, closing a stake of 737,464 shares — an estimated $494K sold.

Nuveen first reported a position in SGMO in Q2 2019 and held it in 20 quarters. The position peaked at $22.5M in Q4 2020. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

  • Nuveen reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 737,464 SANGAMO THERAPEUTICS INC shares in Q2 2024, an estimated $494K.
  • Nuveen first reported a position in SANGAMO THERAPEUTICS INC in Q2 2019 and held it in 20 quarters.
  • Nuveen's SANGAMO THERAPEUTICS INC position peaked at $22.5M in Q4 2020.
  • 129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.